Syncona Portfolio Ltd
- SEC CIK
- 0001725042
- Latest filing
- Aug 6, 2026
The latest 13F from Syncona Portfolio Ltd covers Q2 2026 (filed Aug 6, 2026): 1 long positions worth $26.6M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Autolus Therapeutics plc (AUTL) at 100.0%. Livermore has 19 filings on Form 13F from this institution, going back to Q4 2021.
What changed in Q2 2026
Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 0
- Added
- 0
- Reduced
- 0
- Sold out
- 1
- Est. −$2.74M
Biggest buys
New and added positions, by estimated amount bought
None this quarter.
Largest weight increases
New and added positions, by percentage points of the portfolio gained
None this quarter.
Metrics
13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $26.6M
- +$919.5K (+3.6%) vs. prior quarter
- Positions
- 1
- −1 vs. prior quarter
- Top 10 concentration
- 100.0%
- Top 10 as share of value
- Turnover
- 0.0%
- Q2 2026, one quarter
- Average holding period
- 19.0 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q4 2021), so positions held before then are understated.
13F filings by quarter
19 quarters, going back to Q4 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $157.7M (Q4 2023)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | 1 | $26.6M | AUTL | vs. Q1 2026 | SEC |
| Q1 2026 | May 14, 2026 | 2 | $25.7M | AUTLIPSC | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 5, 2026 | 2 | $34.3M | AUTLIPSC | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 6, 2025 | 2 | $27.7M | AUTLIPSC | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 7, 2025 | 2 | $38.6M | AUTLIPSC | vs. Q1 2025 | SEC |
| Q1 2025 | May 7, 2025 | 2 | $26.4M | AUTLIPSC | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 6, 2025 | 3 | $53.0M | AUTLAchilles Therapeutics PLCIPSC | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 14, 2024 | 3 | $80.7M | AUTLAchilles Therapeutics PLCIPSC | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 13, 2024 | 3 | $85.9M | AUTLAchilles Therapeutics PLCIPSC | vs. Q1 2024 | SEC |
| Q1 2024 | May 7, 2024 | 2 | $150.1M | AUTLAchilles Therapeutics PLC | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 1, 2024 | 4 | $157.7M | AUTLAchilles Therapeutics PLCFreeline Therapeutics Hldgs | vs. Q3 2023 | SEC |
| Q3 2023 | Nov 1, 2023 | 4 | $67.1M | AUTLAchilles Therapeutics PLCFreeline Therapeutics Hldgs | vs. Q2 2023 | SEC |
| Q2 2023 | Jul 27, 2023 | 4 | $66.3M | AUTLAchilles Therapeutics PLCFreeline Therapeutics Hldgs | vs. Q1 2023 | SEC |
| Q1 2023 | May 12, 2023 | 4 | $61.5M | AUTLAchilles Therapeutics PLCFreeline Therapeutics Hldgs | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 14, 2023 | 4 | $63.0M | AUTLFreeline Therapeutics HldgsAchilles Therapeutics PLC | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 4, 2022 | 4 | $57.5M | Achilles Therapeutics PLCAUTLFreeline Therapeutics Hldgs | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 10, 2022 | 4 | $70.4M | Achilles Therapeutics PLCAUTLFreeline Therapeutics Hldgs | vs. Q1 2022 | SEC |
| Q1 2022 | May 31, 2022 | 4 | $104.7M | Achilles Therapeutics PLCAUTLFreeline Therapeutics Hldgs | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 11, 2022 | 4 | $104.7M | Achilles Therapeutics PLCAUTLFreeline Therapeutics Hldgs | – | SEC |
13D and 13G filings
Companies where Syncona Portfolio Ltd reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
1 company, largest stake first.
Latest filings
14 filings on file made by Syncona Portfolio Ltd or listing it as a reporting person, newest first.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| AUTLAutolus Therapeutics plc | May 7, 20259:00 AM ET | 13G/A | 10.80%28.8M shares | – | Mar 31, 2025 | SEC |
| AUTLAutolus Therapeutics plc | Nov 14, 2024 | 13G/AOld format | – | – | – | SEC |
| Freeline Therapeutics Holdings plc | Feb 22, 2024 | 13D/AOld format | – | – | – | SEC |
| Achilles Therapeutics plc | Feb 13, 20246:40 PM ET | 13G/AOld format | – | – | – | SEC |
| AUTLAutolus Therapeutics plc | Feb 13, 2024 | 13G/AOld format | – | – | – | SEC |
| Freeline Therapeutics Holdings plc | Nov 24, 2023 | 13D/AOld format | – | – | – | SEC |
| Freeline Therapeutics Holdings plc | Oct 18, 2023 | 13D/AOld format | – | – | – | SEC |
| AUTLAutolus Therapeutics plc | Feb 14, 2023 | 13G/AOld format | – | – | – | SEC |
| Freeline Therapeutics Holdings plc | Mar 25, 2022 | 13DOld format | – | – | – | SEC |
| Achilles Therapeutics plc | Feb 11, 2022 | 13GOld format | – | New | – | SEC |
| AUTLAutolus Therapeutics plc | Feb 11, 2022 | 13G/AOld format | – | – | – | SEC |
| Freeline Therapeutics Holdings plc | Feb 11, 2022 | 13G/AOld format | – | – | – | SEC |
| Freeline Therapeutics Holdings plc | Feb 12, 2021 | 13GOld format | – | New | – | SEC |
| AUTLAutolus Therapeutics plc | Feb 12, 2021 | 13G/AOld format | – | – | – | SEC |